| 3.7 -0.03 (-0.8%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.61 | 1-year : | 4.82 |
| Resists | First : | 3.95 | Second : | 4.13 |
| Pivot price | 3.75  |
|||
| Supports | First : | 3.66 | Second : | 3.04 |
| MAs | MA(5) : | 3.7 |
MA(20) : | 3.8 |
| MA(100) : | 3.7  |
MA(250) : | 3.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 10.2 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 5.19 | Low : | 2.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AVIR ] has closed above bottom band by 23.5%. Bollinger Bands are 59.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.74 - 3.76 | 3.76 - 3.78 |
| Low: | 3.63 - 3.65 | 3.65 - 3.67 |
| Close: | 3.66 - 3.7 | 3.7 - 3.73 |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Wed, 24 Apr 2024
BML Capital Management LLC Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Tue, 09 Apr 2024
Stonepine Capital Management LLC Trims Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Wed, 27 Mar 2024
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral ... - GlobeNewswire
Thu, 29 Feb 2024
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 28 Feb 2024
Atea Pharmaceuticals GAAP EPS of -$0.47 beats by $0.03 - Seeking Alpha
Wed, 28 Feb 2024
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 84 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 67.5 (%) |
| Shares Short | 1,670 (K) |
| Shares Short P.Month | 1,650 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.9 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -85 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -2.27 |
| PEG Ratio | 0 |
| Price to Book value | 0.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|